The result demonstrated that high expression levels of BNIP3, CCND1, ERBB2, and PECAM1 were correlated with better clinical endpoint of ccRCC, while high CEBPB, TIMP1, and UBE2C expression were linked to worse clinical outcome (Figure S3). Here, PECAM1 is linked to nonpapillary renal cell carcinoma.